Search clinical trials for: Secukinumab (75 mg)

Total 10457 results

Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
GL Pharm Tech Corporation

Unknown

The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

Neuropathic Pain

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Ankylosing Spondylitis

India, Turkey, Belgium, Thailand, United States, Czechia, Greece, Russian Federation, Bulgaria, Guatemala, Italy, Korea, Republic of, Malaysia, Sweden, Colombia, Philippines, Poland, Brazil
Novartis Pharmaceuticals

Terminated

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (ORBIT)

Thyroid Eye Disease | Graves Orbitopathy

Germany
Chinese University of Hong Kong

Completed

PsA Secukinumab XCT Structural Progression Study

Psoriatic Arthritis

Hong Kong
Jinnah Postgraduate Medical Centre

Completed

Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Plaque Psoriasis

Pakistan
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals

Terminated

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Necrobiosis Lipoidica Diabeticorum

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE)

Hidradenitis Suppurativa

Belgium, Italy, United Kingdom, United States, Hungary, Malaysia, Germany, Netherlands, France, Israel, Lebanon, Singapore, Spain, Bulgaria, Lithuania, Argentina, Turkey, Guatemala, Switzerland, Vietnam, Philippines, Croatia, India, S... and more
Novartis Pharmaceuticals

Withdrawn

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). (CAIN457X12301)

Active Peripheral Spondyloarthritis (pSpA)
Massachusetts General Hospital
Novartis

Withdrawn

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

United States
Icahn School of Medicine at Mount Sinai
Novartis

Terminated

A Study of Secukinumab for the Treatment of Alopecia Areata

Alopecia Areata

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (PROSE)

Plaque Psoriasis

Germany, United Kingdom, Belgium, Czechia, Estonia, Italy, France, Israel, Spain, Bulgaria, Lithuania, Portugal, Poland, Romania, Latvia, Greece, Slovakia
Diamant Thaci
Novartis

Completed

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients (BIOMARKER)

Psoriasis Vulgaris

Germany
Tanja Todberg, MD

Unknown

Anti-IL-17 a New Treatment for Contact Dermatititis

Allergic Contact Dermatitits

Denmark
Novartis Pharmaceuticals

Terminated

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Novartis Pharmaceuticals

Completed

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE)

Hidradenitis Suppurativa

United States, Spain, Russian Federation, Taiwan, Germany, France, United Kingdom, Korea, Republic of, Japan, Australia, Switzerland, Austria, Italy, Sweden, India, Israel, Mexico, Philippines, Portugal, Turkey, Greece, Hungary, Bul... and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)

Non-radiographic Spondyloarthritis

United States, Spain, Belgium, Hungary, Turkey, Netherlands, Austria, Israel, Sweden, Switzerland, Germany, Korea, Republic of, Australia, Russian Federation, Italy, Portugal, United Kingdom, Bulgaria, France, Czechia, Poland, Japan, Mexi... and more
Janssen Korea, Ltd., Korea

Completed

A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition

Healthy

Korea, Republic of
Labopharm Inc.

Completed

A Comparative Bioavailability/Food Effect Study of Immediate-Release and Extended-Release Tramadol HCl/Acetaminophen Combination Products Following Single-Dose and Multiple-Dose Administration in Healthy Adult Volunteers

Healthy

United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Novartis Pharmaceuticals

Completed

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Alzheimer's Disease

Netherlands, United States, Belgium, Germany, United Kingdom
Mylan Pharmaceuticals Inc

Completed

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

Healthy

United States
University of Pennsylvania
Novartis

Recruiting

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Psoriasis

United States
Janssen Research & Development, LLC

Withdrawn

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Hepatic Impairment
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Ukraine, United States, Czechia, Poland, Argentina, Mexico, South Africa, Chile, Bulgaria, Colombia, Russian Federation
Spanish Oncology Genito-Urinary Group
Apices Soluciones S.L.; Janssen, LP

Completed

Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. (ABIDO)

Metastatic Prostate Cancer

Spain
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy (UnchAIN)

Tendinopathy

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Ankylosing Spondyloarthritis

United Kingdom, Korea, Republic of, China, Czechia
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

Chronic Plaque Psoriasis
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

Healthy

United States
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions

Inflammation
Bill & Melinda Gates Medical Research Institute

Not yet recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Healthy Volunteers

Kenya, Uganda
Daiichi Sankyo Co., Ltd.
Mediscience Planning, Inc.

Completed

A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin

Type 2 Diabetes Mellitus

Japan
University Health Network, Toronto

Active, not recruiting

Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (BIOTAPE)

Axial Spondyloarthritis

Canada
Amgen

Completed

Phase II Study to Evaluate the Efficacy of AMG 317

Asthma
Novartis Pharmaceuticals

Active, not recruiting

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

Argentina, Canada, Guatemala, Mexico, Brazil, Costa Rica, Dominican Republic, Panama
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Stiftung Institut fuer Herzinfarktforschung
Bristol-Myers Squibb; Sanofi

Completed

CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction

Myocardial Infarction

Germany, Austria
Janssen Research & Development, LLC

Completed

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, France, Ukraine, Germany, Israel, Poland, Bulgaria, Romania, Russian Federation, Canada, Netherlands, Belgium, Hungary
Sohag University

Not yet recruiting

Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction

Patient With Anterior Myocardial Infarction

Egypt
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
Novartis Pharmaceuticals

Completed

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (METABOLYX)

Psoriasis | Metabolic Syndrome

Germany
Novartis Pharmaceuticals

Completed

Extension in AS: Sustainability of Benefits, Safety and Tolerability (MEASURE 1 ext)

Spondylitis, Ankylosing

Belgium, Germany, Netherlands, France, United States, Bulgaria, Italy, Mexico, Russian Federation, Peru, United Kingdom, Turkey, Canada, Taiwan
Novartis Pharmaceuticals

Recruiting

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (REPLENISH-EXT)

Polymyalgia Rheumatica

Australia
University of Pennsylvania
Axsome Therapeutics, Inc.

Recruiting

Solriamfetol and CBT-I in Patients With Insomnia Disorder

Insomnia

United States
Janssen Research & Development, LLC
Janssen Pharmaceuticals

Completed

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Influenza A

United States, Germany, Bulgaria, Canada, Estonia, Latvia, Belgium, Puerto Rico

Search clinical trials for: Secukinumab (75 mg)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations